Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Ferran Pérez-Alcántara"'
Autor:
Carlos Escobar, Cristóbal Morales, Margarita Capel, Susana Simón, Ferran Pérez-Alcántara, Elisenda Pomares
Publikováno v:
BMC Health Services Research, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background The objective of this study was to carry out a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of th
Externí odkaz:
https://doaj.org/article/86bdb220c34849f5a8abc423bf6d1bb3
Autor:
Manuel Anguita, José Luis Zamorano, Ferran Pérez-Alcántara, José Manuel Rodríguez, Iñaki Lekuona, Paloma Barja de Soroa
Publikováno v:
Revista Española de Cardiología. 72:398-406
Resumen Introduccion y objetivos Analizar el coste-efectividad del edoxaban frente al acenocumarol en la prevencion del ictus y la embolia sistemica en pacientes con fibrilacion auricular no valvular (FANV) en Espana. Metodos Modelo de Markov, adapta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::030fac0f76bf34e3d1b55fa34b23a144
https://doi.org/10.1016/j.recesp.2018.03.017
https://doi.org/10.1016/j.recesp.2018.03.017
Autor:
Oscar Fernández, José Meca-Lallana, Ana Polanco, Miguel Angel Calleja-Hernández, Ferran Pérez-Alcántara, Celia Oreja-Guevara
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 17:321-333
Multiple Sclerosis (MS) is a progressive disease leading to increasing disability and costs. A literature review was carried out to identify MS costs and to estimate its economic burden in Spain. Areas Covered: The public electronic databases PubMed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4753b96b28cc40c8dbedb48829e21f9e
https://doi.org/10.1080/14737167.2017.1358617
https://doi.org/10.1080/14737167.2017.1358617
Autor:
Ferran Pérez-Alcántara, Vicente Vicente, Manuel Monreal, Ana Vieta, Iciar Martínez-López, Sonia Jiménez, Ruth Graefenhain, David Jiménez
Publikováno v:
PharmacoEconomics Spanish Research Articles. 12:147-156
Determinar el coste-efectividad de rivaroxaban frente al tratamiento convencional (heparinas de bajo peso molecular y acenocumarol) en el tratamiento del tromboembolismo venoso (TEV), que comprende la trombosis venosa profunda (TVP) y la embolia pulm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd02be0bf0729fc47921d28bd459f8d2
https://doi.org/10.1007/s40277-015-0040-8
https://doi.org/10.1007/s40277-015-0040-8
Autor:
José Manuel Rodríguez, Manuel Anguita, Ferran Pérez-Alcántara, José Luis Zamorano, Iñaki Lekuona, Paloma Barja de Soroa
Publikováno v:
Revista espanola de cardiologia (English ed.). 72(5)
Introduction and objectives To assess the cost-effectiveness of edoxaban vs acenocoumarol in the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) in Spain. Methods Markov model, adapted to the Spanish
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de989ad84f41aa709d361f790b5a0452
https://pubmed.ncbi.nlm.nih.gov/31007166
https://pubmed.ncbi.nlm.nih.gov/31007166
Autor:
Cristina Grávalos Castro, Ignasi Campos Tapias, José Antonio Gasquet Espuña, Ferran Pérez-Alcántara
Publikováno v:
PharmacoEconomics Spanish Research Articles. 11:135-145
Objetivo La evidencia cientifica indica similar eficacia y tolerancia de los anticuerpos anti-EGFR panitumumab (Pmab) y cetuximab (Cmab). El objetivo de este estudio es la evaluacion economica de Pmab frente a Cmab con quimioterapia (QT) en \(1^{\rm{
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a75cd453b3f47b03ab8a8528fd1f46
https://doi.org/10.1007/s40277-013-0024-5
https://doi.org/10.1007/s40277-013-0024-5
Autor:
Juan Bautista Galdiz-Iturri, Montse Figueras-Sabaté, Ferran Pérez-Alcántara, Luis Borderías-Clau, Max Brosa-Riestra, Maribel Riera-Febrer
Publikováno v:
PharmacoEconomics Spanish Research Articles. 10:89-97
La enfermedad pulmonar obstructiva cronica (EPOC) es una patologia asociada a una alta morbilidad y caracterizada por una progresiva limitacion del flujo pulmonar. Indacaterol es un nuevo agonista adrenergico beta-2 de larga duracion que combina rapi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bea7c91f3b1d02f7538ea436e5f1a67f
https://doi.org/10.1007/s40277-013-0011-x
https://doi.org/10.1007/s40277-013-0011-x
Autor:
J López-Bastida, C Suarez, C Avendaño, P Barja de Soroa, Ferran Pérez-Alcántara, JM Rodriguez Barrios, JR Gonzalez-Juantey
Publikováno v:
Value in Health. 18(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d713dbf9a25f106ade109e93abb7eaad
Autor:
Fernando Rivera, Javier Sastre, Pilar Bretes Garcia, Ferran Pérez-Alcántara, Joana Gostkorzewicz, Alfredo Carrato, Patricia Benedit, Rafael López, Teresa Macarulla
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 15(4)
The PANCOSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine (GEM) versus GEM alone in the treatment of patients with metastatic pancreatic cancer in Spain. Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae940e1ef0919ea6eae574521e4d8411
https://pubmed.ncbi.nlm.nih.gov/25991037
https://pubmed.ncbi.nlm.nih.gov/25991037
Autor:
Emilio Alba, Eva Ciruelos, Rafael López, José Manuel López-Vega, Ana Lluch, Miguel Martín, Montserrat Muñoz, Pedro Sánchez-Rovira, Miguel Ángel Seguí, null COSTABRAX Working Group, Marta Rubio Liria, Ferran Pérez-Alcántara
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 13(3)
The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the treatment of patients with previously treated metastatic b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b65f2385042dee152cf4b0cedf5f16
https://pubmed.ncbi.nlm.nih.gov/23534988
https://pubmed.ncbi.nlm.nih.gov/23534988